KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-Current Assets (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Non-Current Assets for 13 consecutive years, with $72.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 55.48% to $72.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $552.0 million, a 21.91% decrease, with the full-year FY2025 number at $72.5 million, down 55.48% from a year prior.
  • Non-Current Assets was $72.5 million for Q4 2025 at Xenon Pharmaceuticals, down from $127.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $319.8 million in Q4 2023 to a low of $7.4 million in Q1 2021.
  • A 5-year average of $119.4 million and a median of $140.2 million in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: skyrocketed 1475.28% in 2022, then crashed 55.48% in 2025.
  • Xenon Pharmaceuticals' Non-Current Assets stood at $13.0 million in 2021, then surged by 1084.63% to $153.8 million in 2022, then surged by 107.89% to $319.8 million in 2023, then plummeted by 49.08% to $162.9 million in 2024, then plummeted by 55.48% to $72.5 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Non-Current Assets are $72.5 million (Q4 2025), $127.7 million (Q3 2025), and $174.0 million (Q2 2025).